Phase 4
Completed N=28
Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects
Source: ClinicalTrials.gov NCT00376246 ↗Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: Percent Change in Flow Mediated Dilation — 12.3; 11.6; 10.9; 11.1 percent change
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The objective of this study is to show that Ezetimibe will improve endothelial function following high cholesterol meals in healthy subjects by decreasing absorption of cholesterol and thus affecting concentration and composition of remnant-like particles.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in Flow Mediated Dilation |
12.3; 11.6; 10.9; 11.1; 12.8; 13.9 | — |
| SECONDARY Lipid Profile- Change in LDL(Low Density Lipoprotein) |
92; 102; 89; 104; 87; 101 | — |
Eligibility Criteria
Inclusion Criteria
- healthy adults over 18 yrs of age
Exclusion Criteria
- presence of known metabolic syndrome
- as history of coronary artery disease
- hypertension
- diabetes
- cardiomyopathy
- tobacco use
Data sourced from ClinicalTrials.gov (NCT00376246). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.